BKA
LUMO

Brick & Kyle Associates’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Brick & Kyle Associates’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-22
Closed -$7K – 442
2015
Q3 		$7K Buy
+22
New +$9.66K 0.01% 374

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Brick & Kyle Associates's LUMO Position: Q4 2015 in Review

Brick & Kyle Associates sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2015, closing a stake of 22 shares — an estimated $7K sold.

Brick & Kyle Associates first reported a position in LUMO in Q3 2015 and held it in 1 quarter. The position peaked at $7K in Q3 2015. 152 funds tracked by Wall St. Rank hold LUMO as of Q4 2015.

  • Brick & Kyle Associates reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • Brick & Kyle Associates sold 22 Lumos Pharma, Inc. Common Stock shares in Q4 2015, an estimated $7K.
  • Brick & Kyle Associates first reported a position in Lumos Pharma, Inc. Common Stock in Q3 2015 and held it in 1 quarter.
  • Brick & Kyle Associates's Lumos Pharma, Inc. Common Stock position peaked at $7K in Q3 2015.
  • 152 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2015.

Based on Brick & Kyle Associates's 13F filing for Q4 2015, filed 19 Jan 2016.